Marinus Pharmaceuticals, Inc. (MRNS)
MRNS moved a median of 0.00% 30 minutes after news, and -0.36% by the close. How MRNS actually reacts to news — the realized, point-in-time move the market made, measured across 687 labeled events over the last three years with zero look-ahead.
MRNS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 644 |
| 30-min | 0.00% | 50% | 649 |
| 60-min | 0.00% | 49% | 649 |
| to close | -0.36% | 42% | 649 |
| Middle 50% of MRNS reactions | -0.41% to +1.16% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 687 |
Half of all Marinus Pharmaceuticals, Inc. news events land between -0.41% and +1.16% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MRNS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.22% | 40% | +1.14% |
| Analyst downgrades | 22 | -1.67% | 36% | -0.94% |
| Coverage initiations | 14 | -0.22% | 43% | -0.47% |
| Rating reiterations | 45 | -1.27% | 33% | -0.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MRNS ranks against every other measured name →
That’s how MRNS usually reacts — get an email when it moves on news →Email me when MRNS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MRNS's baseline. Nothing else.
Recent MRNS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G MARINUS PHARMACEUTICALS, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT MARINUS PHARMACEUTICALS, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Feb 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM MARINUS PHARMACEUTICALS, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS MARINUS PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +1.17% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | +1.17% | |
| Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. | Press release | Business Wire | +0.35% | +1.17% | |
| MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.35% | +1.17% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | +9.91% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.29% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -2.48% | -2.65% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.84% | -10.40% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -5.84% | -10.40% | |
| Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Press release | Business Wire | -5.84% | -10.40% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | +2.65% | -39.59% | |
| Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives | Press release | Business Wire | +2.65% | -39.59% | |
| Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting | Press release | Business Wire | -1.65% | -4.40% | |
| Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens | Press release | Business Wire | +2.28% | +2.86% | |
| Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting | Press release | Business Wire | +0.58% | -1.73% | |
| Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | +0.58% | -1.73% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +1.19% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Sep 20 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +2.47% | |
| Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day | Press release | Business Wire | -1.24% | +2.47% | |
| Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 | Press release | Business Wire | -0.71% | -0.71% | |
| Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference | Press release | Business Wire | +0.72% | +1.45% | |
| Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 | Press release | Business Wire | -2.32% | +3.10% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.85% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.85% | |
| Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Press release | Business Wire | +0.00% | +0.85% | |
| Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 | Press release | Business Wire | -1.06% | -1.42% | |
| DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024 | Press release | GlobeNewswire | +0.00% | -0.71% | |
| Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder | Press release | Business Wire | -1.09% | +0.72% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +5.04% | +4.32% | |
| Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus | Press release | Business Wire | +5.04% | +4.32% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +2.01% | |
| Form S-8 MARINUS PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | -0.34% | +2.01% | |
| Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. (MRNS) | Press release | GlobeNewswire | +0.00% | +0.33% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | +5.34% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | +2.31% | |
| Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program | Press release | Business Wire | +2.31% | +2.31% | |
| Form 10-Q MARINUS PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.85% | -8.33% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +3.85% | -8.33% | |
| Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | Business Wire | +3.85% | -8.33% | |
| Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference | Press release | Business Wire | +0.67% | -2.69% | |
| Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 | Press release | Business Wire | +5.00% | +5.00% | |
| Form 8-K MARINUS PHARMACEUTICALS, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +2.21% | -29.73% | |
| Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results | Press release | Business Wire | +2.21% | -29.73% | |
| Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -1.72% | +4.46% | |
| Form DEF 14A MARINUS PHARMACEUTICALS, For: May 22 | SEC filing · Form DEF | SEC EDGAR | -0.91% | -1.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MRNS section they belong to.
Where else MRNS is measured.
MRNS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) | 692 | -0.06% | 49% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| PTC Therapeutics, Inc. (PTCT) | 686 | +0.01% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Marinus Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled MRNS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 687 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of MRNS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MRNS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.